AZ's Alexion Acquisition Looks Astute Bit Of Business
Offers $39bn For Rare Disease Drug Pioneer
Executive Summary
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
You may also be interested in...
AstraZeneca Cashes In Moderna Chips
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.
Albireo Sets Sights On Rare Disease Model
Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.
AZ Brushes Off Vaccine Criticism, Awaits US Readout
While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.
Need a specific report? 1000+ reports available
Buy Reports